Ulcerative Colitis Clinical Trial
— OSTEOMICOfficial title:
Impact of Osteopathy on IBS-like Symptoms Associated With Ulcerative Colitis in Patients in Remission
Verified date | November 2023 |
Source | Clinique Paris-Bercy |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Type : interventional, randomized single blind study Aim : to evaluate 3 sessions of osteopathy on IBS-like symptoms associated with ulcerative colitis in remission Number of patients : 50 (randomization 1:1) Duration of the inclusion period : 2 years Primary end-point : Irritable Bowel Syndrome Severity Scoring System (IBS SSS) at 3 months
Status | Terminated |
Enrollment | 8 |
Est. completion date | November 2, 2021 |
Est. primary completion date | November 2, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 90 Years |
Eligibility | Inclusion Criteria: - Signed informed consent - Age between 18 and 90 - Patient with ulcerative colitis (whatever the Montreal grade, E1, E2 or E3) In clinical remission for at least 3 months and with fecal calprotectin < 200 µg/g - No modification of Ulcerative Colitis treatment for at least 3 months - Patient with IBS-liked symptoms defined as in Rome IV classification for Irritable Bowel Syndrome - Patient with Irritable Bowel Syndrome Severity Scoring System > 75 at screening - Patient affiliated to the French Social Security regimen Exclusion Criteria: - Patient refusal - Patient < 18 yoa - Patient with colonic or ileal stenosis - Patient diagnosed as undetermined colitis - Patient not in remission for Ulcerative Colitis as defined by an endoscopic Mayo score > 1 within the 3 months preceding the inclusion and/or fecal calprotectin > 200 µg/g at inclusion - Osteopathy session(s) within 1 month before inclusion - Patient with Inflammatory rheumatic disorders (ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis) - Patient with Irritable Bowel Syndrome Severity Scoring System <75 at screening - Patient above 18 yoa with law guardianship |
Country | Name | City | State |
---|---|---|---|
France | Clinique Paris Bercy | Charenton Le Pont |
Lead Sponsor | Collaborator |
---|---|
Clinique Paris-Bercy |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Evaluate the score change of Irritable Bowel Syndrome Severity Scoring System (IBS SSS) | index of severity of Irritable Bowel Syndrome symptoms | Month 1, Month 2, Month 3, Month 4 | |
Secondary | IBDQol : Inflammatory Bowel Disease Questionnaire | Index of quality of life dedicated to Inflammatory Disease Bowel patients : the score is high, better the quality of life | Month 1, Month 2, Month 3, Month 4 | |
Secondary | FACIT-F : Functional Assessment of Chronic Illness Therapy-Fatigue | Validated fatigue score with question about quality of life 45/5000
if the score is high, the patient is tired |
Month 1, Month 2, Month 3, Month 4 | |
Secondary | Evaluation of osteopathic dysfunctions | it will be interesting to see if patients with remission-prone RCH have similar osteopathic dysfunctions at the beginning of the study, and then if the management during the study influences or not these osteopathic dysfunctions.
Osteopathic dysfunction is an alteration of the mobility, viscoelasticity or texture of somatic system components. It is accompanied or not by a painful sensibility. |
Month 1, Month 2, Month 3, Month 4 | |
Secondary | Questionnaire for use of medication for Irritable Bowel Syndrome | if treatment modification, dose reduction or change in treatment | Month 1, Month 2, Month 3, Month 4 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05702879 -
Combined Microbiota and Metabolic Signature in Ulcerative Colitis Predicts Anti-Inflammatory Therapy Success
|
||
Not yet recruiting |
NCT05953402 -
A Study of Ozanimod in Pregnant Women With Ulcerative Colitis and Their Offspring
|
||
Recruiting |
NCT05316584 -
A Novel Remote Patient and Medication Monitoring Solution to Improve Adherence and PerSiStence With IBD Therapy
|
N/A | |
Recruiting |
NCT03950232 -
An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis
|
Phase 3 | |
Completed |
NCT03124121 -
Study of the Golimumab Exposure-Response Relationship Using Serum Trough Levels
|
Phase 4 | |
Not yet recruiting |
NCT06100289 -
A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease
|
Phase 3 | |
Withdrawn |
NCT04209556 -
A Study To Evaluate The Safety And Efficacy Of PF-06826647 In Participants With Moderate To Severe Ulcerative Colitis
|
Phase 2 | |
Terminated |
NCT00061282 -
Clotrimazole Enemas for Pouchitis in Children and Adults
|
Phase 1/Phase 2 | |
Recruiting |
NCT04398550 -
SCD vs. Mediterranean Diet Therapy in Ulcerative Colitis
|
N/A | |
Recruiting |
NCT04314375 -
Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Extended-release Tablets in Pediatric Subjects Aged 5 to 17 Years With Active, Mild to Moderate Ulcerative Colitis
|
Phase 4 | |
Active, not recruiting |
NCT04857112 -
Study Evaluating Efficacy and Safety of Amiselimod (MT-1303) in Mild to Moderate Ulcerative Colitis
|
Phase 2 | |
Completed |
NCT05051943 -
A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
|
||
Active, not recruiting |
NCT04033445 -
A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis
|
Phase 2/Phase 3 | |
Recruiting |
NCT05428345 -
A Study of Vedolizumab SC Given to Adults With Moderate to Severe Ulcerative Colitis or Crohn's Disease in South Korea
|
||
Active, not recruiting |
NCT06221995 -
Energy Expenditure in Patients With Ulcerative Colitis Undergoing Surgery
|
||
Recruiting |
NCT04767984 -
Testing Atorvastatin to Lower Colon Cancer Risk in Longstanding Ulcerative Colitis
|
Phase 2 | |
Completed |
NCT02508012 -
Medico-economic Evaluation of the Therapeutic Drug Monitoring of Anti-TNF-α Agents in Inflammatory Bowel Diseases
|
N/A | |
Recruiting |
NCT06071312 -
FMT in Patients With Recurrent CDI and Ulcerative Colitis: Single Infusion Versus Sequential Approach
|
Phase 1/Phase 2 | |
Completed |
NCT03760003 -
Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis
|
Phase 2 | |
Not yet recruiting |
NCT05539625 -
Mini-MARVEL - Mitochondrial Antioxidant Therapy in Ulcerative Colitis
|
Phase 2 |